| Literature DB >> 31374198 |
Mark D McKenzie1, Margherita Ghisi2, Ethan P Oxley2, Steven Ngo2, Luisa Cimmino3, Cécile Esnault4, Ruijie Liu1, Jessica M Salmon2, Charles C Bell5, Nouraiz Ahmed6, Michael Erlichster7, Matthew T Witkowski8, Grace J Liu9, Michael Chopin10, Aleksandar Dakic10, Emilia Simankowicz2, Giovanna Pomilio11, Tina Vu2, Pavle Krsmanovic12, Shian Su1, Luyi Tian7, Tracey M Baldwin1, Daniela A Zalcenstein1, Ladina DiRago13, Shu Wang14, Donald Metcalf15, Ricky W Johnstone5, Ben A Croker16, Graeme I Lancaster17, Andrew J Murphy17, Shalin H Naik7, Stephen L Nutt18, Vitek Pospisil12, Timm Schroeder6, Meaghan Wall19, Mark A Dawson5, Andrew H Wei11, Hugues de Thé4, Matthew E Ritchie20, Johannes Zuber21, Ross A Dickins22.
Abstract
Tumors are composed of phenotypically heterogeneous cancer cells that often resemble various differentiation states of their lineage of origin. Within this hierarchy, it is thought that an immature subpopulation of tumor-propagating cancer stem cells (CSCs) differentiates into non-tumorigenic progeny, providing a rationale for therapeutic strategies that specifically eradicate CSCs or induce their differentiation. The clinical success of these approaches depends on CSC differentiation being unidirectional rather than reversible, yet this question remains unresolved even in prototypically hierarchical malignancies, such as acute myeloid leukemia (AML). Here, we show in murine and human models of AML that, upon perturbation of endogenous expression of the lineage-determining transcription factor PU.1 or withdrawal of established differentiation therapies, some mature leukemia cells can de-differentiate and reacquire clonogenic and leukemogenic properties. Our results reveal plasticity of CSC maturation in AML, highlighting the need to therapeutically eradicate cancer cells across a range of differentiation states.Entities:
Keywords: PU.1; acute myeloid leukemia; acute promyelocytic leukemia; cancer stem cell; differentiation therapy; leukemia stem cell; myelopoiesis; pioneer factor; retinoic acid; transcription factor
Year: 2019 PMID: 31374198 DOI: 10.1016/j.stem.2019.07.001
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633